Methotrexate Hospira Uk (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to regenerate tetrahydrofolate. This limits the synthesis of nucleotides required for DNA replication, thereby reducing the proliferation of rapidly dividing cells in the immune system and in malignant tumors.

The specific dose and schedule of Methotrexate Hospira Uk are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosing regimens are individualized and should follow the prescriber’s instructions.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate shares a similar mechanism with other folate antagonists but is distinguished by its broad therapeutic range, including both autoimmune diseases and various cancers. Compared with agents like pemetrexed, methotrexate has a longer history of use and a well‑characterized safety profile, though monitoring requirements are comparable.

Methotrexate Hospira Uk should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze. Follow any additional handling instructions provided with the shipment to maintain product integrity.

The product is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intrathecal routes, depending on the clinical indication and prescriber’s recommendation. Administration should be performed by qualified healthcare professionals using aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to infection or bleeding, and renal failure. Patients should be monitored regularly for hepatic, pulmonary, renal, and hematologic parameters, and any signs of toxicity should prompt immediate medical evaluation.

Methotrexate is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, active infections, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with pre‑existing blood dyscrasias.